Body-on-a-chip systems for animal-free toxicity testing

Traditional toxicity testing relies heavily on animal models, which may not accurately reflect human physiology. Prior research has shown that animal-based testing can lead to misleading results when applied to human drug responses. This gap motivated the development of alternative systems that better represent human biology. It was already known that animal models often fail to predict human toxicity accurately. That uncertainty drove the search for more reliable in vitro platforms. No prior work had resolved how to simulate human organ interactions effectively. Scientists sought methods to integrate multiple human tissues in a controlled setting. This article addresses the progress made in replacing animal testing with human-relevant models.

The goal of this review is to assess the current state of body-on-a-chip systems for toxicity testing. These systems aim to replicate human physiology in a controlled environment. The specific problem addressed is the lack of accurate, animal-free models for drug testing. The motivation stems from the limitations of animal models in predicting human outcomes. Researchers aim to evaluate how well these systems can simulate human metabolism and toxicity. The review focuses on progress made since the 2015 Lush Science Prize. The authors seek to highlight the potential of these systems to replace animal testing. The study emphasizes the importance of human-derived tissues in improving test accuracy.

The review approach includes analyzing published data on body-on-a-chip systems. The authors examine how these systems model organ size and blood flow. They assess the use of human-derived tissues in these platforms. The study evaluates the ability of these systems to simulate drug metabolism. The researchers compare the performance of animal models versus human-based systems. They consider the role of induced pluripotent stem cells in tissue generation. The analysis includes functional responses such as electrical and mechanical tissue activity. The authors synthesize findings from multiple studies to assess overall progress.

Key findings from the literature show that body-on-a-chip systems can replicate human organ size and blood flow. These systems enable the simulation of drug metabolism and toxic effects. Human-derived tissues allow for accurate modeling of prodrug activation. The systems can measure tissue electrical and mechanical responses. Studies suggest that these platforms improve the prediction of drug toxicity. They provide a more human-relevant alternative to animal models. The use of iPS-derived tissues enhances the accuracy of these simulations. The review highlights the potential of these systems to replace animal testing.

Synthesis and implications from the literature indicate that body-on-a-chip systems offer a viable alternative to animal testing. These systems can simulate human metabolism and toxicity with high accuracy. The use of human-derived tissues improves the relevance of test results. The authors propose that these systems can reduce reliance on animal models. They suggest that further development is needed to optimize system performance. The review implies that these platforms can accelerate drug development. The findings support the potential of body-on-a-chip systems in preclinical trials. The authors emphasize the importance of continued research in this area.